WO2021069836A1 - Masquage du goût de l'isosorbide - Google Patents
Masquage du goût de l'isosorbide Download PDFInfo
- Publication number
- WO2021069836A1 WO2021069836A1 PCT/FR2020/051766 FR2020051766W WO2021069836A1 WO 2021069836 A1 WO2021069836 A1 WO 2021069836A1 FR 2020051766 W FR2020051766 W FR 2020051766W WO 2021069836 A1 WO2021069836 A1 WO 2021069836A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isosorbide
- equal
- beads
- gelled
- gelled beads
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Definitions
- the present technology relates to masking the taste of isosorbide, in particular its bitterness.
- the technology developed here thus provides a new dosage form to improve the taste of isosorbide, as well as a process for preparing this dosage form.
- Isosorbide is an osmotic diuretic used in the treatment of Méimba's disease in several countries. This active principle, which needs to be ingested in large quantities, is known for its extremely unpleasant taste, in particular its strong bitterness.
- a dose of isosorbide consists of the oral absorption of sticks of 40 mL at 70% isosorbide (ie 28 g of isosorbide administered per dose).
- no method has until now been found which effectively masks the taste of isosorbide, in particular considering the concentrations and quantities ingested.
- the present invention thus aims to provide an effective means for masking the taste of isosorbide, in particular when this active principle is administered in large quantities, and / or at high concentrations.
- This oral dosage form is in the form of gelled isosorbide beads, preferably using alginate as a gelling agent.
- the dosage form proposed by the present invention is simple to implement, in that it does not require the use of a large number of materials.
- isosorbide is a small, highly soluble molecule, it is surprising that bitterness is not felt, especially considering the amounts and concentrations administered. Indeed, one would have expected that isosorbide would diffuse beads very quickly into the saliva of the oral cavity, where its bitterness would have been detected by the taste buds, and therefore felt by the panel of tasters.
- document WO2006 / 001344 relates to a gelled mass based on alginate isosorbide and other gelling constituents. Such a composition is not suitable for making beads.
- this document teaches that taste masking is optimized by adding cocoa powder.
- Document US2010 / 120712 relates to a composition comprising these two ingredients, said composition being in the form of extruded granules or powders. Compositions in the form of beads are not described.
- document WO 00/06122 describes pharmaceutical compositions for oral administration comprising particles of active principle and a gelling agent.
- the particles of active principle can optionally be in the form of alginate beads (Example 12).
- the particles of active ingredient obtained are mixed with a gelling agent and other substances, in order to obtain the final dosage form.
- this solid form is added with water to obtain a gelled composition and the undesirable taste of the active ingredient is masked.
- This document does not mention isosorbide, and the pharmaceutical compositions finally ingested contain very small amounts of the active ingredient.
- the invention relates firstly to gelled beads, in particular for oral administration, comprising isosorbide, the isosorbide content being at least 50% by dry weight of isosorbide relative to the weight. total of said gelled beads.
- the invention relates secondly to a pharmaceutical composition comprising or consisting of the gel beads of the invention.
- the invention relates thirdly to a process for preparing the gelled beads of the invention, said process comprising the following steps:
- step (b) preparation of a gelation solution
- step (c) dropwise addition of the solution prepared in step (a), to the gelling solution prepared in step (b);
- the invention relates to a method of masking the unwanted taste of isosorbide, comprising putting said isosorbide in the form of gel beads.
- the invention relates firstly to gelled beads, in particular for oral administration, comprising isosorbide, the isosorbide content being at least 50% by dry weight of isosorbide relative to the total weight of said. gel beads.
- this dry weight content of isosorbide is at least 60%, preferably at least 70%, preferably at least 75%, more preferably at least 80%.
- This isosorbide dry weight content is generally less than or equal to 95%, or even less than or equal to 90%, or even less than or equal to 85%.
- This content by dry weight of isosorbide relative to the total weight of said gelled beads can be determined by a person skilled in the art, for example by gas chromatography with flame ionization detection and internal calibration, preferably using the methyl aD-glucopyranoside as internal standard, for example according to a protocol described in the examples below.
- the gelled beads of the invention typically comprise one or more gelling agent (s).
- Gelling agents capable of rapidly gelling at room temperature in the presence of water are particularly useful herein. They are preferably polymers capable of undergoing crosslinking gelation in the presence of polyvalent metal ions.
- Gelling agents include among others those agents which are capable of gelling when used in combination. Examples of gelling agents are alginates, pectates, carrageenans and gelatin. Preferably, gelatin will not be used, in particular due to the fact that it is a product of animal origin. Preferably, as gelling agent, at least the alginate will be used. When several gelling agents are present, the proportion by dry weight of alginate is then preferably at least 20% relative to the total dry weight of gelling agents, preferably at least 30%, preferably at least. at least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%. More preferably, the alginate is the only gelling agent of the gelled beads.
- these gelling agents are in the form of salts, for example sodium, magnesium, potassium, preferably sodium. Particularly preferred is sodium alginate.
- the gelling agents used have a Brookfield viscosity, as measured at 1% at 20 ° C, less than or equal to 2000 cps, preferably less than or equal to 1000 cps, preferably less than or equal to 800 cps , preferably less than or equal to 500 cps, preferably less than or equal to 400 cps, preferably less than or equal to 300 cps, preferably less than or equal to 250 cps, preferably less than or equal to 200 cps.
- a Brookfield viscosity as measured at 1% at 20 ° C, less than or equal to 2000 cps, preferably less than or equal to 1000 cps, preferably less than or equal to 800 cps , preferably less than or equal to 500 cps, preferably less than or equal to 400 cps, preferably less than or equal to 300 cps, preferably less than or equal to 250 cps, preferably less than or equal to 200 cps.
- this Brookfield viscosity is greater than or equal to 10 cps, preferably greater than or equal to 20 cps, preferably greater than or equal to 30 cps, preferably greater than or equal to 35 cps, preferably greater than or equal to 50 cps, preferably greater than or equal to 80 cps, preferably greater than or equal to 100 cps.
- This viscosity is for example chosen from a range going from 35 to 65 cps, or from 100 to 200 cps, or from 300 to 400 cps.
- the content by dry weight of gelling agents relative to the total dry weight of the gelled beads (dry / dry), in particular the content of alginate is at least 0.1%, of preferably at least 0.3%, preferably at least 0.5%, preferably at least 0.7%, preferably at least 1.0%, preferably at least 1 , 2%, preferably at least 1.4%.
- This content by dry / dry weight of gelling agents or more particularly of alginate is preferably less than or equal to 5.0%, preferably less than or equal to 4.0%, preferably less than or equal to 3.0%, preferably less than or equal to 2.0%, preferably less than or equal to 1.8%, preferably less than or equal to 1.6%.
- the gelled beads of the invention exhibit an isosorbide / gelling agent dry weight ratio at least equal to 40, preferably at least equal to 50, preferably at least equal to 55, preferably at least equal to 60.
- This ratio is preferably less than or equal to 200, preferably less than or equal to 150, preferably less than or equal to 140, preferably less than or equal to 130, preferably less than 120, preferably less than or equal to 100, preferably less than or equal to 80, preferably less than or equal to 75.
- the gelled beads of the invention exhibit an isosorbide / alginate dry weight ratio at least equal to 40, preferably at least equal to 50, preferably at least equal to 55, preferably at least equal to 60.
- This ratio is preferably less than or equal to 200, preferably less than or equal to 150, preferably less than or equal to 140, preferably less than or equal to 130, preferably less than 120, preferably less than or equal to 100, preferably less than or equal to 80, preferably less than or equal to 75.
- the gelled beads of the present invention comprise a solvent, preferably water, even more preferably demineralized water.
- the solvent content of the gelled beads is less than or equal to 30% by weight relative to the total weight of gelled beads, preferably less than or equal to 25%, preferably less than or equal to 20%, for example less than or equal to 18%.
- This solvent content is generally greater than or equal to 1%, or even greater than or equal to 5%, or even greater than or equal to 10%, for example greater than or equal to 13%, 14% or 15%.
- Gelled beads may contain ions, usually in the form of traces, depending on the process used for their preparation.
- the gelled beads may contain other substances than those listed above, as long as this does not contravene the desired properties, in particular as regards the taste quality of the gelled beads, and / or their stability, and / or the pharmacological activity of isosorbide.
- other substances are, for example: flavorings; sweeteners, especially intense sweeteners; encapsulating agents such as cyclodextrins; active ingredients other than isosorbide; compounds aimed at modifying the bioavailability of the active principles of the beads, in particular aimed at modifying the bioavailability of isosorbide.
- the gelled beads comprise less than 30% by dry weight of other substances relative to the total weight of gelled beads, preferably less than 20%, preferably less than 10%, preferably less than 5%, preferably less than 1%, more preferably 0%. It has in fact been demonstrated in the examples below that the other substances are not necessary for solving the problem posed here.
- the gelled beads are free from other substances.
- the gelled beads in this case consist only of isosorbide, gelling agents, and a solvent which is preferably water, more preferably demineralized water.
- the gelled beads consist only of isosorbide, alginate and a solvent which is preferably water, more preferably demineralized water.
- the gelled beads have an average diameter less than or equal to 5.0 mm, preferably less than or equal to 3.0 mm, preferably less than or equal to 2.0 mm, preferably less than or equal to 1.5 mm.
- This average diameter is generally greater than or equal to 0.1 mm, or even greater than or equal to 0.2 mm, or even greater than or equal to 0.3 mm, or even greater than or equal to 0.4 mm, or even greater than or equal to 0 , 5 mm.
- the beads are insoluble in water at a temperature of 20 ° C.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising the gelled beads of the invention.
- isosorbide fulfills the role of active principle.
- pharmaceutical composition is meant a composition in its final dosage form intended to be administered to a patient.
- This pharmaceutical composition can also consist only of the gel beads of the invention.
- the gelled beads can quite be administered as they are.
- the gel beads can be administered with other substances, for example in the form of a suspension of the gel beads in a syrup.
- the pharmaceutical composition of the invention contains an amount of isosorbide per intake of at least 10 g, preferably at least 20 g, preferably at least 25 g, for example 28 g.
- the pharmaceutical composition of the invention is intended to be administered 1, 2 or 3 times per day, preferably 3 times per day.
- the pharmaceutical composition of the invention contains an isosorbide content of at least 20% by dry weight relative to the total weight of said pharmaceutical composition, preferably at least 30% by dry weight, of preferably at least 40% by dry weight, preferably at least 50% by dry weight, preferably at least 60% by dry weight, preferably at least 70% by dry weight, preferably d at least 75% by dry weight, more preferably at least 80% by dry weight.
- This isosorbide dry weight content is generally less than or equal to 95%, or even less than or equal to 90%, or even less than or equal to 85%.
- the pharmaceutical composition according to the invention is for use as a medicament, in particular for the treatment of Mérier's disease.
- Another object of the invention relates to a method of treatment, in particular of Mérier's disease, comprising the administration of a pharmaceutical composition of the invention.
- it is a composition for its use in the treatment of Mérier's disease.
- the composition according to the invention for the manufacture of a medicament intended for therapeutic use in Mérier's disease.
- the patient to be treated is an individual suffering from Méayne's disease.
- a subject of the present invention is also a process for preparing gelled beads according to the invention, said process comprising the following steps:
- step (c) dropwise addition of the solution prepared in step (a), to the gelling solution prepared in step (b);
- the gelling agent is solubilized first in a solvent which is preferably water, more preferably demineralized water, and the isosorbide is then added.
- a solvent which is preferably water, more preferably demineralized water, and the isosorbide is then added.
- the solution of step (a) has an isosorbide content chosen from a range of 30 to 80% by weight relative to the total weight of said solution.
- this content is at least equal to 40%, preferably at least equal to 45%, preferably at least equal to 50%, preferably at least equal to 55%.
- this content is at most equal to 80%, preferably at most equal to 75%, preferably at most equal to 70%, preferably at most equal to 65%. This content is for example equal to 50%, or to 60%.
- the solution of step (a) has a content of gelling agents, in particular an alginate content, chosen in a range ranging from 0.1 to 5.0% by weight relative to the total weight. of said solution.
- this content is at least equal to 0.2%, preferably at least equal to 0.3%, preferably at least equal to 0.4%, preferably at least equal to 0.5%.
- this content is maximum equal to 4.5%, preferably maximum equal to 4.0%, preferably maximum equal to 3.5%, preferably maximum equal to 3.0%, preferably at most equal to 2.5%, preferably at most equal to 2.0%, preferably at most equal to 1.5%, preferably at most equal to 1.0%.
- the amounts of isosorbide and gelling agents in the solution of step (a) are chosen such that the weight ratio isosorbide / gelling agents is at least equal to 40, preferably at least equal to 50, preferably at least equal to 60.
- This ratio is preferably less than or equal to 200, preferably less than or equal to 150, preferably less than or equal to 140, preferably less than or equal to 110, preferably less than or equal to 100.
- the amounts of isosorbide and alginate in the solution of step (a) are chosen such that the isosorbide / alginate weight ratio is at least equal to 40, preferably at least equal to 50, preferably at least equal to 60.
- This ratio is preferably less than or equal to 200, preferably less than or equal to 150, preferably less than or equal to 140, preferably less than or equal to 110, preferably less than or equal to 100.
- the total amount of solids in the solution of step (a) is chosen from a range of 30 to 80% by weight relative to the total weight of said solution.
- this amount of solids is chosen from a range of 50 to 70%, preferably 60 to 65%.
- the gelation solution of step (b) comprises one or more polyvalent metal ion (s).
- the gelling agents of the invention are preferably polymers capable of undergoing crosslinking gelation in the presence of polyvalent metal ions.
- the gelling solution can be a solution having a temperature lower than that of the solution of step (a), so that gelling occurs by cooling.
- These polyvalent metal ions are for example chosen from calcium, aluminum, iron, copper, zinc ions or a mixture thereof.
- Calcium ions are particularly preferred.
- These calcium ions can preferably be in the form of inorganic salts such as calcium chloride, calcium sulfate, calcium monohydrogenophosphate or calcium carbonate. They can also be in the form of organic salts such as calcium lactate, calcium gluconate, calcium citrate. Preferably, it is a water soluble salt.
- the polyvalent metal ions useful in the invention comprise at least chloride of calcium. More preferably, calcium chloride is the only polyvalent metal ion used.
- the polyvalent metal ions are in the form of water insoluble salts (as is the case for example of calcium carbonate), it will be necessary to add an acid to dissolve the salt, in particular an organic acid such as citric acid, adipic acid, glucono-delta-lactone acid etc. Therefore, calcium salts which are soluble in water, in particular calcium chloride, are preferably used.
- the gelation solution of step (b) has a content of polyvalent metal ions, in particular a content of calcium chloride, chosen in a range ranging from 1 to 20% by dry weight relative to the content. total weight of said solution.
- this content is at least equal to 3%, preferably at least equal to 5%, preferably at least equal to 7%, preferably at least equal to 9%.
- this content is at most equal to 18%, preferably at most equal to 16%, preferably at most equal to 14%, preferably at most equal to 12%, preferably at most equal to 11%. This content is for example equal to 10%.
- step (c) it is possible to pump the solution of step (a) contained in a storage unit in order to bring it to the gelling solution contained in another. storage unit.
- the pump used will typically depend on the viscosity of the solution from step (a) containing the gelling agent (s). Adding the solution prepared in step (a) dropwise to the gelation solution prepared in step (b) allows the instantaneous formation of beads.
- the process for preparing gelled beads further comprises, between steps (c) and (d), a step of washing the gelled beads, preferably with demineralized water.
- This step is typically carried out in order to rid the product of salts optionally used in the process, such as, for example, calcium chloride.
- the process for preparing gelled beads preferably comprises a step of drying the gelled beads, between steps (c) and (d). This step will preferably be subsequent to the washing step if the latter is carried out. This drying can be carried out in an oven. On an industrial scale, however, techniques using the action of a heated air flow applied to the moving balls will be preferred. An example is drying in a fluidized air bed.
- Drying in addition to increasing the stability of the gel beads, also has the effect of reducing the diameter of the beads. So to control the desired diameter, in addition to choosing a suitable system for the formation of the drops to gel, it will be necessary to take into account the effect of this heating step.
- the gelled beads Preferably before drying, the gelled beads contain a liquid core. Indeed in this case, the drying step will advantageously be able to concentrate the isosorbide of the beads.
- the gelled beads do not contain a liquid core.
- the present invention also relates to gelled beads, in particular for oral administration, which may be obtained by or obtained by according to the process for preparing gelled beads of the invention.
- gelled beads in particular for oral administration, which may be obtained by or obtained by according to the process for preparing gelled beads of the invention.
- the preferred embodiments of these gelled beads are as described before, in the description relating to the gelled beads.
- Another object of the invention relates to a method for masking the unwanted taste of isosorbide, comprising putting said isosorbide in the form of gel beads.
- the gelled beads make it possible to statistically significantly reduce the bitterness of isosorbide, compared to an isosorbide solution having the same concentration and quantity of isosorbide, said bitterness being detected by an electronic tongue equipped with lipid membrane bitterness sensors for example using equipment such as Insent® Electronic Taste Sensing System TS-5000Z (Atsugi-Chi, Japan) equipped for example with bitterness sensors SB2AC0 (Bitterness 1, cationic substances), SB2AN0 (Bitterness 2, cationic substances) and SB2C00 (Bitterness 3, anionic substances).
- the gelled beads make it possible to statistically significantly improve the taste of isosorbide, compared to an isosorbide solution having the same concentration and quantity of isosorbide, said improvement being determined using a panel of tasters.
- the gelled beads make it possible to completely mask the undesirable taste of the isosorbide, and in particular its bitterness.
- the gelled beads are as described before.
- the isosorbide is formed into gelled beads by the process for preparing gelled beads of the invention as described above.
- an amount by “dry weight” refers to an amount by weight of anhydrous substance.
- an amount simply expressed in “weight” refers to amounts of so-called “commercial” materials, that is to say to quantities of generally powdery product used as such. These contents by weight therefore include the water which may be inherently present in these commercial powders.
- the isosorbide and the salts typically and preferably contain 0% by weight of water, and that the gelling agents, in particular the alginate, comprise a maximum of 15% by weight of water.
- Example 1 Masking of the taste of isosorbide using intense sweeteners (liquid medium)
- Example 2 Masking of the taste of isosorbide using encapsulation techniques (liquid medium)
- Example 3 Masking of the taste of isosorbide using texturing techniques (gelled medium) [80]
- Various formulations in gel form were tested, in order to examine the effectiveness of texturing techniques for masking the taste. isosorbide.
- the formulations used are presented in Tables 5 and 6 below, and the percentages are expressed by weight relative to the total weight of the formulation.
- isosorbide was ground (Moulin IKA) beforehand, in order to facilitate its solubilization.
- Formulations with the MCC / CMC compound and pectin had limited impact on isosorbide bitterness, even when strong sweeteners were added to the formulation.
- Formulations based on soluble hydrolyzed hydroxypropyl pea starch failed to improve the taste of the isosorbide.
- Example 4 Masking of the taste of isosorbide using texturing techniques (gelled medium) and the use of flavorings [86]
- the inventors attempted to improve the gels of Example 3 which had only a limited impact on the bitterness of the isosorbide.
- gels with added flavorings were tested.
- the formulations used are presented in Tables 7 and 8 below, and the percentages are expressed by weight relative to the total weight of the formulation.
- the isosorbide was ground (Moulin IKA) beforehand, in order to facilitate its solubilization.
- Example 5 Masking of the taste of isosorbide by the formation of gelled beads
- a gelation solution [B] was then prepared, consisting of 90% by weight of demineralized water, and 10% by weight of calcium chloride.
- the resulting beads had a diameter of about 2-3 mm. They were then dried in an oven, and then had a diameter of about 1 mm.
- Beads obtained from Formulation 38 were analyzed by gas chromatography with flame ionization detection and internal calibration to determine their isosorbide dry weight content.
- the capillary column used had a length of 30 meters, an internal diameter of 0.32 millimeters, a film thickness of 1 micron.
- the isosorbide content is expressed in dry g per 100 g of gelled beads and is given by the following equation:
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022520491A JP7797379B2 (ja) | 2019-10-07 | 2020-10-07 | イソソルビドの味のマスキング |
| EP20796640.9A EP4041197A1 (fr) | 2019-10-07 | 2020-10-07 | Masquage du goût de l'isosorbide |
| US17/754,498 US20240050375A1 (en) | 2019-10-07 | 2020-10-07 | Masking the taste of isosorbide |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1911102A FR3101546B1 (fr) | 2019-10-07 | 2019-10-07 | Masquage du goût de l’isosorbide |
| FR1911102 | 2019-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021069836A1 true WO2021069836A1 (fr) | 2021-04-15 |
Family
ID=70456810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2020/051766 Ceased WO2021069836A1 (fr) | 2019-10-07 | 2020-10-07 | Masquage du goût de l'isosorbide |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240050375A1 (fr) |
| EP (1) | EP4041197A1 (fr) |
| JP (1) | JP7797379B2 (fr) |
| FR (1) | FR3101546B1 (fr) |
| WO (1) | WO2021069836A1 (fr) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006122A1 (fr) | 1998-07-31 | 2000-02-10 | Otsuka Pharmaceutical Co., Ltd. | Composition pharmaceutique ayant un gout ameliore |
| WO2006001344A1 (fr) | 2004-06-24 | 2006-01-05 | Sanwa Kagaku Kenkyusho Co., Ltd. | Préparation de gelée contenant de l'isosorbide |
| US20100120712A1 (en) | 2007-01-10 | 2010-05-13 | Setsuko Takeda | Pharmaceutical composition for meniere's disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68915494T2 (de) * | 1988-03-09 | 1995-01-05 | Snow Brand Milk Prod Co Ltd | Zubereitung mit verzögerter freigabe durch verwendung von alginaten. |
| JPH0889177A (ja) * | 1994-09-29 | 1996-04-09 | Nippon Suisan Kaisha Ltd | 魚類用有効成分投与ビーズ |
| JPH09208495A (ja) * | 1996-01-26 | 1997-08-12 | Kyorin Pharmaceut Co Ltd | 薬物の苦味を低減した粒状製剤及びその製造方法 |
| US6432449B1 (en) * | 1998-05-18 | 2002-08-13 | Amgen Inc. | Biodegradable sustained-release alginate gels |
| JP4105732B2 (ja) * | 2006-03-01 | 2008-06-25 | 節子 竹田 | メニエール病治療薬 |
| JP4881268B2 (ja) * | 2006-09-25 | 2012-02-22 | あすか製薬株式会社 | 苦味が抑制された経口製剤 |
| JP4081131B1 (ja) * | 2007-01-10 | 2008-04-23 | 節子 竹田 | メニエール病治療薬 |
| JP2011079784A (ja) * | 2009-10-08 | 2011-04-21 | Nisshin Seiyaku Kk | 不快な味を隠蔽した経口薬剤 |
-
2019
- 2019-10-07 FR FR1911102A patent/FR3101546B1/fr active Active
-
2020
- 2020-10-07 EP EP20796640.9A patent/EP4041197A1/fr active Pending
- 2020-10-07 US US17/754,498 patent/US20240050375A1/en active Pending
- 2020-10-07 JP JP2022520491A patent/JP7797379B2/ja active Active
- 2020-10-07 WO PCT/FR2020/051766 patent/WO2021069836A1/fr not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006122A1 (fr) | 1998-07-31 | 2000-02-10 | Otsuka Pharmaceutical Co., Ltd. | Composition pharmaceutique ayant un gout ameliore |
| WO2006001344A1 (fr) | 2004-06-24 | 2006-01-05 | Sanwa Kagaku Kenkyusho Co., Ltd. | Préparation de gelée contenant de l'isosorbide |
| US20100120712A1 (en) | 2007-01-10 | 2010-05-13 | Setsuko Takeda | Pharmaceutical composition for meniere's disease |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7797379B2 (ja) | 2026-01-13 |
| FR3101546A1 (fr) | 2021-04-09 |
| FR3101546B1 (fr) | 2023-11-10 |
| JP2022550858A (ja) | 2022-12-05 |
| US20240050375A1 (en) | 2024-02-15 |
| EP4041197A1 (fr) | 2022-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2672961B1 (fr) | Granules effervescents d'acide gamma-hydroxybutyrique | |
| EP2605757B1 (fr) | Formulations a base de nalbuphine et leurs utilisations | |
| EP3212164B1 (fr) | Granules de principe actif a double masquage de gout, leur procede de preparation et comprimes orodispersibles les contenant | |
| WO2003045166A1 (fr) | Capsule a solubilisation et liberation du contenu rapides | |
| EP1100467A1 (fr) | Procede de fabrication de particules de gabapentine ou de pregabaline enrobees | |
| CA2682250A1 (fr) | Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique | |
| EP0300897A2 (fr) | Dispositif à libération contrôlée qui fournit une délivrance continue d'un principe actif de manière contrôlée et compositions à particules multiples contenant de tels dispostifs | |
| EP1401397B1 (fr) | Formulation pharmaceutique au gout masque et son procede de preparation | |
| EP2131823B1 (fr) | Film monocouche a desintegration rapide pour l'administration buccale de substances actives | |
| EP1098931B1 (fr) | Hydrogels polyioniques a base de xanthane et chitosane pour stabilisation et relargage controle des vitamines | |
| WO2010015754A1 (fr) | Composition pharmaceutique sous forme de granules et procede de fabrication d'une telle composition pharmaceutique | |
| WO2019158873A1 (fr) | Composition multiusage de torasemide | |
| EP4041197A1 (fr) | Masquage du goût de l'isosorbide | |
| EP2879663B1 (fr) | Pastilles a cinetiques multiples de liberation de principes actifs | |
| FR3005262A1 (fr) | Nouvelles compositions pharmaceutiques ou dietetiques permettant de masquer totalement l'amertume des sels d'arginine donnes a haute dose, sous forme liquide ou semi-liquide. | |
| EP1032372B1 (fr) | Masquant pour gouts pharmaceutiques en poudre | |
| EP4352110A1 (fr) | Procede de modification d'amidon par traitement hydro-thermique, amidon obtenu par ce procede et ses utilisations | |
| EP0412877A1 (fr) | Nouvelle forme galénique orale améliorant la biodisponibilité | |
| EP1316317A1 (fr) | Associations hydrosolubles à base de cyprotérone et/ou d'un ester de celle-ci, leurs préparations et leurs utilisations | |
| EP0239481A1 (fr) | Comprimé-retard de théophylline à base de P.V.C., et son procédé de préparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20796640 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2022520491 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 17754498 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2020796640 Country of ref document: EP Effective date: 20220509 |













